Treatment of chronic hepatitis C in Lombardia: An analysis on the safety and efficacy of DAA therapy in 5457 patients
Alessio Aghemo, S. Fagiuoli(Ospedale Papa Giovanni XXIII), Paolo Grossi(University of Insubria), Tiziana Quirino(Ospedale di Circolo di Busto Arsizio), S. Zaltron(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), L. Pasulo(Ospedale Papa Giovanni XXIII), Silvia Fargion(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Massimo Zuin(AOL (United States)), Franco Maggiolo(Ospedale Papa Giovanni XXIII), A. Corbellini(ASST Melegnano e della Martesana), Maria Grazia Rumi(University of Milan), Angelo Pan(Istituti Ospitalieri di Cremona), Giuliano Rizzardini, R. Bruno, Angelo Rossini(Centro Universitário Barão de Mauá), Massimo Puoti(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda)
Cited by 0
Related Papers
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
|Gastroenterology|2016|1k
Antiretroviral Treatment of Adult HIV Infection
|JAMA|2010|725
Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study
|The Lancet. Gastroenterology & hepatology|2022|664
Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response.
|Journal of Clinical Investigation|1996|661
Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission
|The Lancet. Gastroenterology & hepatology|2019|539